Jerome S Connor, 822918 Big Meadows Dr, Humble, TX 77339

2006012, Jun 15, 2006

Jan 18, 2006

11/334950

Stephen Livesey - Victoria, AU
Michael Burnett - Houston TX, US
Jerome Connor - The Woodlands TX, US
Christopher Wagner - Houston TX, US

A61K 35/14
A01N 1/02
A61K 31/70
A61K 31/7048
A61K 31/522
A61K 31/7012

424093700, 435002000, 514027000, 514263310, 514053000, 514449000

A red blood cell storage composition includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence the biochemistry altering reagents. The red blood cell storage composition preferably includes reagents selected from: modifiers of glycolytic/metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of specific messenger molecules, and combinations thereof.

2012014, Jun 7, 2012

Feb 8, 2012

13/368460

Stephen A. Livesey - Eltham, AU
Michael Brian Burnett - Houston TX, US
Jerome Connor - The Woodlands TX, US
Christopher Todd Wagner - Houston TX, US

A01N 1/02

435 2

A red blood cell storage composition includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence the biochemistry altering reagents. The red blood cell storage composition preferably includes reagents selected from: modifiers of glycolytic/metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of specific messenger molecules, and combinations thereof.

5622867, Apr 22, 1997

Oct 19, 1994

8/326036

Stephen A. Livesey - Eltham, AU
Jerome Connor - Houston TX
Laura M. Currie - Houston TX

Lifecell Corporation - The Woodlands TX

A61K 3514

436 18

This invention provides a method for prolonging the preservation of human blood platelets at reduced temperatures. The method uses an inhibitor system that enables blood platelets to maintain their discoid shape and retain their functional integrity during storage. This is accomplished by interrupting normal platelet function during storage, so as to help keep platelets from activating and losing their shape. Before using the platelets in a transfusion, they are returned to their normal functional level by washing the inhibitor system away from the platelets.

5919614, Jul 6, 1999

May 8, 1997

8/852921

Stephen A. Livesey - Conroe TX
Jerome Connor - The Woodlands TX
Laura M. Currie - Houston TX

LifeCell Corporation - The Woodlands TX

A01N 102

435 2

This invention provides a method for prolonging the preservation of human blood platelets at reduced temperatures. The method uses an inhibitor system that enables blood platelets to maintain their discoid shape and retain their functional integrity during storage. This is accomplished by interrupting normal platelet function during storage, so as to help keep platelets from activating and losing their shape. Before using the platelets in a transfusion, they are returned to their normal functional level by washing the inhibitor system away from the platelets. In particular, compositions comprising amiloride, adenosine and sodium nitroprusside are disclosed.

6221669, Apr 24, 2001

Feb 13, 1996

8/600343

Stephen A. Livesey - Conroe TX
Jerome Connor - The Woodlands TX
Laura M. Currie - Spring TX

LifeCell Corporation - Branchburg NJ

G01N 3100
A61K 3514

436 18

This invention provides a method for prolonging the preservation of human blood platelets at reduced temperatures. The method uses an inhibitor system that enables blood platelets to retain their functional integrity during storage. In addition, the inhibitor system prevents the generation of cytokines in the platelet preparation during storage at both 22. degree. C. and 4. degree. C. This is accomplished by interrupting normal platelet function during storage, so as to help keep platelets from activating and losing their shape. Before using the platelets in a transfusion, they are returned to their normal functional level by washing the inhibitor system away from the platelets.